These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1164 related articles for article (PubMed ID: 12639811)

  • 1. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.
    Seccia TM; Belloni AS; Guidolin D; Sticchi D; Nussdorfer GG; Pessina AC; Rossi GP
    J Hypertens; 2006 Jul; 24(7):1419-27. PubMed ID: 16794493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.
    Vora JP; Oyama TT; Thompson MM; Anderson S
    Diabetes; 1997 Jan; 46(1):107-12. PubMed ID: 8971089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
    Braun C; Kleemann T; Hilgenfeldt U; Riester U; Rohmeiss P; van der Woude FJ
    Kidney Int; 2002 Jun; 61(6):2149-56. PubMed ID: 12028455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.
    Tschöpe C; Reinecke A; Seidl U; Yu M; Gavriluk V; Riester U; Gohlke P; Graf K; Bader M; Hilgenfeldt U; Pesquero JB; Ritz E; Unger T
    Am J Physiol; 1999 Dec; 277(6):H2333-40. PubMed ID: 10600853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat.
    van Dijk DJ; Boner G; Giler S; Erman A
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):193-8. PubMed ID: 11881122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.
    Buléon M; Allard J; Jaafar A; Praddaude F; Dickson Z; Ranera MT; Pecher C; Girolami JP; Tack I
    Am J Physiol Renal Physiol; 2008 May; 294(5):F1249-56. PubMed ID: 18367657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.
    Arbin V; Claperon N; Fournié-Zaluski MC; Roques BP; Peyroux J
    Br J Pharmacol; 2000 Jul; 130(6):1297-304. PubMed ID: 10903969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
    Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
    Schäfer S; Schmidts HL; Bleich M; Busch AE; Linz W
    Br J Pharmacol; 2004 Sep; 143(1):27-32. PubMed ID: 15289289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
    Nolly H; Miatello R; Damiani MT; Abate CD
    Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.